Briquilimab

A potent and differentiated c-Kit inhibitor proven to drive mast cell depletion.

Briquilimab is a humanized, aglycosylated, antibody that directly inhibits the binding of SCF with the c-Kit receptor leading to blocking of the c-Kit signaling pathway and mast cell apoptosis..​ The interaction of SCF with c-Kit has been well characterized as essential to mast cell survival, and blocking the interaction has been demonstrated to lead directly to mast cell apoptosis via the Bim-mediated pathway. For many immunological and inflammatory diseases, including chronic urticaria and asthma, this removes the underlying source of the inflammatory response.

Briquilimab was designed to block c-Kit signaling on mast cells while retaining normal antibody clearance characteristics. This allows Jasper to purse an optimal biologic dosing strategy that leads to depletion of mast cells followed by a drug-free interval allowing return of c-Kit signaling on other cells to minimize any unwanted effects.